Clinical trials
Glioma clinical trials
Below are recruiting glioma clinical trials, each written for real people, not researchers. We’re tracking 339 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06636162RecruitingEarly Phase 1
Testing DSP-0390 before surgery for gliomas
This trial tests a drug called DSP-0390 in people with gliomas (a type of brain tumor). You take the drug for a short time before your scheduled surgery to see how it affects the tumor. It might help doctors find new ways to treat these tumors.
St Louis, MissouriAges 18 years+ - NCT06666712RecruitingPhase 1
Chronic brain infusion of topotecan for recurrent glioma
This trial tests a treatment called topotecan that is delivered directly into the brain through a small tube (convection-enhanced delivery). It is for people whose IDH-mutant glioma has come back despite standard treatment. The goal is to see if this approach can help control the tumor.
New York, New YorkAges 18 years+ - NCT06720727Recruiting
Radiation therapy for children with histone-altered midline glioma
This trial tests a type of radiation therapy called craniospinal irradiation for children and teenagers newly diagnosed with a specific brain tumor (diffuse midline glioma with H3 histone alteration). The goal is to see if this radiation can help control the tumor.
MumbaiAges 3–18 - NCT06736470Recruiting
Fluorescence measurement of brain tumor suction samples
This trial is testing a new way to measure fluorescence in fluid suctioned from the brain during glioma surgery. It may help surgeons better identify tumor tissue.
Kuopio, KuopioAges 18 years+ - NCT06801730RecruitingPhase 2
Irinotecan liposomes plus bevacizumab for recurrent glioma
This trial tests a combination of two medications—irinotecan liposomes (a chemotherapy drug wrapped in fat particles) and bevacizumab (a drug that cuts off blood supply to tumors)—for people whose glioma (a type of brain tumor) has come back or worsened after initial treatment. The goal is to see if this combination can help control the tumor.
Lishui, ZhejiangAges 18–75 - NCT06810544RecruitingPhase 1/Phase 2
Study of TNG456 for tumors with MTAP loss
This trial tests a new drug called TNG456, alone or with another drug (abemaciclib), for people whose tumors have lost the MTAP gene. It aims to see if the combination can shrink tumors or slow their growth.
Scottsdale, ArizonaAges 18 years+ - NCT06818331RecruitingPhase 2
Electroacupuncture study for recurring brain cancer
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
China, Hangzhou City, Zhejiang ProvinceAges 18–70 - NCT06828341RecruitingEarly Phase 1
CAR-T cell therapy for recurrent brain glioma
This trial tests a new type of immune cell therapy (CAR-T cells) made from donor cells, designed to target tumors with a specific marker called CD70. It is for people whose brain glioma has come back or hasn't responded to standard treatments.
China, JiangsuAges 18 years+ - NCT06829173RecruitingEarly Phase 1
Testing a new drug with radiation for aggressive brain tumors
This trial tests a new oral drug called XRD-0394 given together with radiation therapy for people with high-grade glioma, a type of aggressive brain tumor. The goal is to see if adding this drug makes radiation more effective.
New York, New YorkAges 18 years+ - NCT06831773Recruiting
Carbon ion radiation for high-grade brain tumors
This trial tests a precise type of radiation called carbon ion radiotherapy for people with aggressive brain tumors (high-grade gliomas). It aims to see if this treatment is safe and effective for patients who have not had radiation to the head before.
Wuwei, GansuAges 14–80 - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Duarte, CaliforniaAges 18 years+ - NCT06883214Recruiting
MiRNA signatures in glioma diagnosis
This study looks at three specific molecules in glioma tumors to understand their role and potentially improve diagnosis. It may help people with glioma by providing more targeted information about their condition.
Rome, RomeAges Any age - NCT07025018RecruitingPhase 1
Study of HMPL-306 for brain tumors with IDH mutations
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07076498RecruitingPhase 1
Gene therapy for children and adults with diffuse midline glioma
This trial tests a modified herpes virus (M032) given directly into the brain tumor after standard radiation. The goal is to see if this virus can slow or stop the growth of diffuse midline glioma, a type of brain cancer.
Houston, TexasAges 3 years+ - NCT07077616RecruitingEarly Phase 1
Personalized vaccine for recurrent glioma
This trial tests a personalized vaccine created by AI to target your specific brain tumor. It is for people with a glioma that came back after standard treatments like surgery, radiation, or chemotherapy, and whose tumor has enough genetic mutations to make the vaccine.
ThessalonikiAges 18 years+ - NCT07159607Recruiting
PET scan for IDH-mutant brain tumors
This trial uses a special PET scan to see how IDH-mutant gliomas respond to treatment. It may help your doctor better track your tumor's activity.
ViennaAges 18 years+ - NCT07240662Recruiting
Vorasidenib for IDH-mutant Grade 2 glioma
This trial tests the drug vorasidenib for people with a slow-growing brain tumor (Grade 2 glioma) that has an IDH mutation. The goal is to see how well the drug works and how it affects your quality of life.
HeidelbergAges 18 years+ - NCT07025226RecruitingEarly Phase 1
Combination drugs and vaccine for glioma with remaining tumor
This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.
Rochester, MinnesotaAges 18 years+ - NCT07263711Recruiting
AI for Brain Tumor Gene Prediction Study
This study is testing if artificial intelligence (AI) can look at microscope slides of your brain tumor tissue to guess its genetic makeup. It uses data already collected from your routine care, so there is no extra treatment or medicine involved.
Guangzhou, GuangdongAges 18–100 - NCT07286903Recruiting
Fluorescence-guided brain tumor surgery study
This trial tests a technique called fluorescence-enhanced surgery to help surgeons see and remove high-grade gliomas more clearly. It uses a special dye (5-ALA) that makes tumor cells glow during surgery.
MilanAges 18 years+ - NCT07346144RecruitingPhase 1/Phase 2
Gene therapy study for high-grade glioma
This trial tests a new gene therapy given directly into the brain tumor. It's for people with high-grade glioma, either newly diagnosed or after one recurrence, to see if it can help control the tumor.
Columbus, OhioAges 18–70 - NCT01906385RecruitingPhase 1/Phase 2
Recurrent brain tumor study testing rhenium nano-liposome
This early-phase study tests a drug made of tiny fat-like particles carrying rhenium for recurrent (coming back) high-grade glioma. It mainly checks safety and the highest tolerable dose, and it also looks for signs the treatment may slow tumor growth.
Manhasset, New YorkAges 18 years+ - NCT02686229Recruiting
Registry study for adults with suspected low-grade brain tumor
This study records health details about adults who may have a low-grade glioma (a slower-growing brain tumor) based on scan results. Researchers use these data to better understand disease patterns and outcomes, and help connect individual patients to future research.
UlmAges 18 years+ - NCT03048084RecruitingPhase 4
Testing seizure medicines after a first seizure in brain tumors
This trial studies which seizure medicine works best for adults who recently had their first seizure caused by certain brain tumors. It may help reduce seizures and improve daily functioning while choosing the right medicine after the first episode.
AmsterdamAges 18 years+
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glioma?
- Yes. Clin2 currently lists 339 recruiting glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.